Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard
G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for
lymphoma.
The investigators hypothesize that after stem cell mobilization with G-CSF plus IV AMD3100, a
significantly higher proportion of lymphoma patients will collect ≥ 2 x 10E6 CD34+ cells/kg.